ABEONA THERAPEUTICS INC. Proceeds from Issuance of Convertible Preferred Stock
ABEONA THERAPEUTICS INC. (ABEO) reported Proceeds from Issuance of Convertible Preferred Stock of $22.47 million for the 12-month period ending 2022-12-31, per its 10-K filed 2024-03-18.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock · last filed 2024-03-18
- ABEONA THERAPEUTICS INC. proceeds from issuance of convertible preferred stock for the quarter ending 2022-12-31 was $0.00.
- ABEONA THERAPEUTICS INC. proceeds from issuance of convertible preferred stock for the quarter ending 2022-09-30 was $0.00.
- ABEONA THERAPEUTICS INC. proceeds from issuance of convertible preferred stock for fiscal 2022 was $22.47M.
| Period end | Proceeds from Issuance of Convertible Preferred Stock 3 month | Proceeds from Issuance of Convertible Preferred Stock 6 month | Proceeds from Issuance of Convertible Preferred Stock 9 month | Proceeds from Issuance of Convertible Preferred Stock 12 month |
|---|---|---|---|---|
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-18 | $0.00 derived: sum of 2 quarters · filed 2024-03-18 | $22.47M 10-K · filed 2024-03-18 | |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $22.47M 10-Q · filed 2023-11-13 | ||
| 2022-06-30 | $22.47M 10-Q · filed 2023-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |